U.S. FDA approves expanded Camzyos indication for adults and pediatric patients with symptomatic OHCM
BMY•The U.S. FDA approved an expanded indication for Bristol Myers Squibb’s Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients.
1. Expanded indication
The U.S. Food and Drug Administration approved an expanded indication for Bristol Myers Squibb’s Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients.
